Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer

Summary

Participation Requirements

Description

This is a translational pilot study, involving two patient cohorts, designed to identify predictive biomarkers for HER2 targeted therapy, which will be validated in a larger future study. Cohort 1: 300 newly diagnosed (including metastatic) HER2 positive breast cancer patients. Cohort 2: 30 newly di...

This is a translational pilot study, involving two patient cohorts, designed to identify predictive biomarkers for HER2 targeted therapy, which will be validated in a larger future study. Cohort 1: 300 newly diagnosed (including metastatic) HER2 positive breast cancer patients. Cohort 2: 30 newly diagnosed HER2 negative breast cancer patients. Blood specimens will be taken: before starting treatment (cohort 1 and 2) after receiving chemotherapy and before starting HER2 targeted treatment (if applicable) (cohort 1) within one month following 1st treatment of HER2 targeted treatment (cohort 1) approximately every 3 months (coinciding with formal disease assessment) while on HER2 targeted treatment for a maximum of 5 years (cohort 1) Blood will be processed to serum, which will be analysed for RNA and protein biomarkers.

Tracking Information